摘要
目的:观察多磺酸黏多糖乳膏联合异维A酸红霉素凝胶治疗轻中度红斑毛细血管扩张型玫瑰痤疮的疗效。方法:选取2019年1月-2021年12月在笔者医院确诊的60例轻中度红斑毛细血管扩张型玫瑰痤疮患者,采用简单随机分组将患者分为观察组和对照组,每组30例。对照组患者采用异维A酸红霉素凝胶治疗,观察组采用多磺酸黏多糖乳膏联合异维A酸红霉素凝胶治疗,均持续治疗6周。分别于治疗前后,记录皮损情况;采用使用玫瑰痤疮医师全球评分(PGA)对患者玫瑰痤疮情况进行评分;使用皮肤病生活质量指数量表(DLQI)评估患者生活质量。记录两组治疗期间的不良反应发生情况。结果:观察组治疗的有效率为86.67%,高于对照组的63.33%(P<0.05)。治疗后,观察组患者皮损情况评分、PGA评分和DLQI评分均明显低于对照组(P<0.05)。观察组患者不良反应发生率为10.00%,低于对照组患者的23.33%,差异无统计学意义(P>0.05)。结论:多磺酸黏多糖乳膏联合异维A酸红霉素凝胶治疗可以明显提高玫瑰痤疮患者的临床疗效,改善皮损情况,提高患者生活质量。
Objective To observe the curative effect of polysulfonic acid mucopolysaccharide cream combined with isotretinoin erythromycin gel on mild to moderate erythematotelangiectatic rosacea.Methods A total of 60 patients with mild to moderate erythematotelangiectatic rosacea confirmed in the hospital were enrolled between January 2019 and December 2021.According to simple random grouping method,they were divided into observation group and control group,30 cases in each group.The control group was treated with isotretinoin erythromycin gel,while observation group was additionally treated with polysulfonic acid mucopolysaccharide cream.All were continuously treated for 6 weeks.Before and after treatment,skin lesions were recorded.The rosacea conditions of patients were scored by physician’s global assessment(PGA).The quality of life was assessed by dermatology life quality index(DLQI).The occurrence of adverse reactions during treatment in both groups was recorded.Results The response rate of treatment in observation group was higher than that in control group(86.67%vs 63.33%,P<0.05).After treatment,scores of skin lesions,PGA and DLQI in observation group were significantly lower than those in control group(P<0.05),and incidence of adverse reactions was lower than that in control group(10.00%vs 23.33%,P>0.05).Conclusion Polysulfonic acid mucopolysaccharide cream combined with isotretinoin erythromycin gel can significantly improve clinical curative effect on rosacea patients,improve skin lesions and quality of life.
作者
佘慧慧
李媛媛
王心培
刘婧
SHE Huihui;LI Yuanyuan;WANG Xinpei;LIU Jing(Department of Dermatology,the Fourth Affiliated Hospital of Nanjing Medical University,Nanjing 210031,Jiangsu,China)
出处
《中国美容医学》
CAS
2022年第11期66-69,共4页
Chinese Journal of Aesthetic Medicine